IS2689B - Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts - Google Patents

Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts

Info

Publication number
IS2689B
IS2689B IS8385A IS8385A IS2689B IS 2689 B IS2689 B IS 2689B IS 8385 A IS8385 A IS 8385A IS 8385 A IS8385 A IS 8385A IS 2689 B IS2689 B IS 2689B
Authority
IS
Iceland
Prior art keywords
dihydroxyheptin
methylsulfonyl
pyrimidin
fluorophenyl
isopropyl
Prior art date
Application number
IS8385A
Other languages
English (en)
Other versions
IS8385A (is
Inventor
Rebecca Jane Booth
Peter Anthony Cittern
Jeffrey Norman Crabb
John Horbury
David Wyn Calvert Jones
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34276833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2689(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0321127A external-priority patent/GB0321127D0/en
Priority claimed from GB0404859A external-priority patent/GB0404859D0/en
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of IS8385A publication Critical patent/IS8385A/is
Publication of IS2689B publication Critical patent/IS2689B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
IS8385A 2003-09-10 2006-03-30 Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts IS2689B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0321127A GB0321127D0 (en) 2003-09-10 2003-09-10 Chemical compounds
GB0404859A GB0404859D0 (en) 2004-03-04 2004-03-04 Chemical compound
PCT/GB2004/003829 WO2005023779A1 (en) 2003-09-10 2004-09-08 Crystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6 -enoicacid] calcium salt

Publications (2)

Publication Number Publication Date
IS8385A IS8385A (is) 2006-03-30
IS2689B true IS2689B (is) 2010-10-15

Family

ID=34276833

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8385A IS2689B (is) 2003-09-10 2006-03-30 Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts

Country Status (31)

Country Link
US (4) US20060293355A1 (is)
EP (1) EP1663989B1 (is)
JP (1) JP2007505090A (is)
KR (1) KR20070019943A (is)
CN (1) CN1878760B (is)
AR (1) AR045628A1 (is)
AT (1) ATE428701T1 (is)
AU (1) AU2004270467B8 (is)
BR (1) BRPI0414236A (is)
CA (1) CA2537962C (is)
CO (1) CO5670355A2 (is)
CY (1) CY1109173T1 (is)
DE (1) DE602004020640D1 (is)
DK (1) DK1663989T3 (is)
ES (1) ES2324042T3 (is)
HR (1) HRP20090335T1 (is)
IL (1) IL174073A (is)
IS (1) IS2689B (is)
MX (1) MXPA06002761A (is)
MY (1) MY142615A (is)
NO (1) NO336358B1 (is)
NZ (1) NZ545785A (is)
PL (1) PL1663989T3 (is)
PT (1) PT1663989E (is)
RU (1) RU2363697C2 (is)
SA (1) SA04250297B1 (is)
SI (1) SI1663989T1 (is)
TW (1) TWI370817B (is)
UA (1) UA85062C2 (is)
UY (1) UY28501A1 (is)
WO (1) WO2005023779A1 (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
IL159741A0 (en) * 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
BR0317313A (pt) 2002-12-16 2005-11-08 Astrazeneca Uk Ltd Processo para a preparação de um composto, e, composto
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
WO2008036286A1 (en) * 2006-09-18 2008-03-27 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
SI2752407T1 (sl) * 2009-01-14 2016-07-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalni kalcijev rosuvastatin trihidrat
AU2010205464A1 (en) * 2009-01-15 2011-08-18 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Process for the preparation of rosuvastatin salts
HUP0900285A2 (en) 2009-05-07 2011-01-28 Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag Rosuvastatin salts and preparation thereof
WO2011074016A1 (en) 2009-12-17 2011-06-23 Matrix Laboratories Ltd Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
US9249108B2 (en) 2010-11-22 2016-02-02 Basf Se Multicomponent system of rosuvastatin calcium salt and sorbitol
US8716305B2 (en) 2011-04-18 2014-05-06 Basf Se Multicomponent crystalline system of rosuvastatin calcium salt and vanillin
WO2014050874A1 (ja) * 2012-09-27 2014-04-03 東和薬品株式会社 ロスバスタチンカルシウムの新規結晶形態およびその製造方法
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
JP6596339B2 (ja) 2014-02-06 2019-10-23 株式会社エーピーアイ コーポレーション ロスバスタチンカルシウム及びその中間体の製造方法
US10626093B2 (en) 2016-04-18 2020-04-21 Morepen Loboratories Limited Polymorphic form of crystalline rosuvastatin calcium and novel processes for crystalline as well as amorphous rosuvastatin calcium
CN105837516B (zh) * 2016-05-16 2018-07-10 山东新时代药业有限公司 一种瑞舒伐他汀钙晶型及其制备方法
US11446757B2 (en) 2017-09-13 2022-09-20 Jfe Steel Corporation Double-sided friction stir welding method for metal sheets and double-sided friction stir welding device
JP7677460B2 (ja) 2023-01-25 2025-05-15 Ｊｆｅスチール株式会社 テーラードブランク材、ならびに、テーラードブランク材の製造方法および製造設備

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) * 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
JPH03501613A (ja) 1988-10-06 1991-04-11 サンド・アクチエンゲゼルシヤフト ピリミジニル置換ヒドロキシ酸、ラクトン及びエステル並びにそれらを含む製薬学的組成物
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) * 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
EP0577040B1 (de) * 1992-07-02 1997-09-24 Hoechst Aktiengesellschaft Verfahren zur Herstellung von (3R,5S)6-Hydroxy-3,5-0-isopropyliden-3,5-dihydroxy-hexansäure-tert.-butylester
EA000474B1 (ru) 1995-07-17 1999-08-26 Варнер-Ламберт Компани Кристаллическая кислая кальциевая соль [r-(r*, r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1н-пиррол-1-гептановой кислоты (аторвастатин)
US6278001B1 (en) * 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
ATE234282T1 (de) 1996-06-24 2003-03-15 Novartis Pharma Gmbh Polymorphe verbindungen
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CA2320163C (en) * 1998-12-10 2008-09-23 Kaneka Corporation Process for producing simvastatin
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
AU7717500A (en) 1999-09-30 2001-04-30 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
CZ20021642A3 (cs) 1999-11-17 2003-05-14 Teva Pharmaceutical Industries Ltd. Polymorfní formy atorvastatinu vápenatého
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
PL361230A1 (en) 2000-10-05 2004-10-04 Biogal Gyogyszergyar Rt. Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
EP1341785B1 (en) 2000-11-16 2008-10-08 Teva Pharmaceutical Industries Ltd. Hydrolysis of r(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
IN190564B (is) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
KR20040007657A (ko) * 2001-06-06 2004-01-24 브리스톨-마이어스 스큅 컴퍼니 키랄 디올 술폰 및 디히드록시산 ＨＭＧ ＣｏＡ 환원효소억제제의 제조 방법
IL159741A0 (en) 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
JP4188826B2 (ja) 2001-08-16 2008-12-03 テバ ファーマシューティカル インダストリーズ リミティド カルシウム塩型スタチンの製造方法
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
JP2005503393A (ja) 2001-08-22 2005-02-03 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド インドール誘導体の製造方法
WO2003026573A2 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP1323717A1 (en) * 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
WO2003097614A2 (en) 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
BR0317313A (pt) * 2002-12-16 2005-11-08 Astrazeneca Uk Ltd Processo para a preparação de um composto, e, composto
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
US7161004B2 (en) * 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
MX2007016203A (es) 2005-06-29 2008-03-10 Compumedics Ltd Ensamble de sensor con puente conductivo.
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
IS8385A (is) 2006-03-30
CO5670355A2 (es) 2006-08-31
CY1109173T1 (el) 2014-07-02
EP1663989B1 (en) 2009-04-15
MXPA06002761A (es) 2006-12-14
AU2004270467A1 (en) 2005-03-17
NO336358B1 (no) 2015-08-03
CN1878760A (zh) 2006-12-13
AU2004270467B8 (en) 2008-09-18
HRP20090335T1 (hr) 2009-07-31
IL174073A0 (en) 2006-08-01
CN1878760B (zh) 2011-11-09
CA2537962A1 (en) 2005-03-17
US20120059022A1 (en) 2012-03-08
DE602004020640D1 (de) 2009-05-28
NO20061181L (no) 2006-03-29
US20130225622A1 (en) 2013-08-29
AU2004270467B2 (en) 2008-08-21
BRPI0414236A (pt) 2006-10-31
IL174073A (en) 2014-03-31
EP1663989A1 (en) 2006-06-07
KR20070019943A (ko) 2007-02-16
TWI370817B (en) 2012-08-21
HK1090361A1 (en) 2006-12-22
PT1663989E (pt) 2009-06-09
NZ545785A (en) 2010-03-26
AR045628A1 (es) 2005-11-02
US8436167B2 (en) 2013-05-07
JP2007505090A (ja) 2007-03-08
UY28501A1 (es) 2005-04-29
CA2537962C (en) 2012-10-23
ATE428701T1 (de) 2009-05-15
ES2324042T3 (es) 2009-07-29
SA04250297B1 (ar) 2008-11-18
TW200526595A (en) 2005-08-16
SI1663989T1 (sl) 2009-08-31
US20060293355A1 (en) 2006-12-28
UA85062C2 (uk) 2008-12-25
WO2005023779A1 (en) 2005-03-17
RU2006111354A (ru) 2007-10-27
US20100222373A1 (en) 2010-09-02
MY142615A (en) 2010-12-15
RU2363697C2 (ru) 2009-08-10
DK1663989T3 (da) 2009-07-06
PL1663989T3 (pl) 2009-08-31

Similar Documents

Publication Publication Date Title
IS2689B (is) Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
IS8478A (is) Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess
ATE382610T1 (de) Cristallinsalze von 7-[4-(4-fluorophenyl)-6- isopropyl-2-[methyl(methylsulfonyl)amino pyrimidin-5-yl -(3r,5s)-3,5-dihydroxyhept-6- ensäure
IS2820B (is) Samsettar samsetningar sem ná yfir (E)-7-[4-(4-flúorofenýl)-6-ísóprópyl-2-[metýl(metýlsúlfónýl)-amínó]pýrimídín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru
IS2805B (is) Lyfjaefnablanda sem inniheldur (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl]-(3R,5S)-3,5-díhýdroxýhept-6-ensýru eða lyfjafræðilega hæft salt þar af
CY2016050I1 (el) Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου
PL1704144T3 (pl) Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego